|
Change of ASX code to BOD
|
15 October 2021 at 1:45pm
|
|
BOD to conduct Schedule 3 clinical trial of new CBD product
|
22 September 2021 at 9:35am
|
|
Change in substantial holding
|
27 August 2021 at 7:20pm
|
|
Investor Presentation
|
25 August 2021 at 9:45am
|
|
Record revenue achieved during FY2021
|
23 August 2021 at 10:05am
|
|
Appendix 4E and Full Year Statutory Accounts
|
23 August 2021 at 9:55am
|
|
Appointment of leading executive as Chief Financial Officer
|
2 August 2021 at 10:20am
|
|
Final Director's Interest Notice
|
21 July 2021 at 10:05am
|
|
Initial Director's Interest Notice - Hanno Cappon
|
21 July 2021 at 10:05am
|
|
Non-Executive Director resignation and appointment
|
21 July 2021 at 10:00am
|
|
Quarterly Activities Report and Appendix 4C
|
15 July 2021 at 9:50am
|
|
212% increase in medicinal cannabis product sales in FY2021
|
1 July 2021 at 9:30am
|
|
Bod broadens UK sales footprint
|
17 June 2021 at 10:10am
|
|
Results of Meeting
|
4 June 2021 at 2:40pm
|
|
Launch of new medicinal cannabis product and UK update
|
18 May 2021 at 10:10am
|
|
Highest ever monthly sales of medicinal cannabis products
|
10 May 2021 at 9:45am
|
|
Notice of Extraordinary General Meeting/Proxy Form
|
30 April 2021 at 11:05am
|
|
Quarterly acitivities report and Appendix 4C
|
22 April 2021 at 9:40am
|
|
Appointment of leading executive as Chief Financial Officer
|
12 April 2021 at 10:30am
|
|
Bod secures first binding purchase order for US market
|
7 April 2021 at 9:40am
|
|
Record medicinal cannabis sales achieved during Q3 FY2021
|
31 March 2021 at 10:05am
|
|
Collaboration agreement with Drug Science for long-COVID
|
18 March 2021 at 9:40am
|
|
Strong half driven by international expansion
|
25 February 2021 at 9:40am
|
|
Half Year Accounts and Appendix 4D
|
25 February 2021 at 9:40am
|
|
Amendment to 30 June 2020 financial statements
|
24 February 2021 at 6:05pm
|
|
Resignation of Chief Financial Officer
|
19 February 2021 at 5:00pm
|
|
Quarterly Activities Report and Appendix 4C
|
28 January 2021 at 10:10am
|
|
Bod delivers record attributable sales in Q2 FY2021
|
18 January 2021 at 9:45am
|
|
Bod achieves strong second half medicinal cannabis sales
|
7 January 2021 at 9:55am
|
|
Change of Director Interest Notices - J Patterson and A Bedi
|
31 December 2020 at 10:30am
|
|
Appendix 3G
|
24 December 2020 at 12:05pm
|
|
Section 708A cleansing notice
|
22 December 2020 at 12:50pm
|
|
$871,413 in binding orders secured for the Italian market
|
22 December 2020 at 9:55am
|
|
Appendix 2A
|
18 December 2020 at 11:55am
|
|
Medical advisory board formed to capitalise on TGA decision
|
16 December 2020 at 9:55am
|
|
Proposed issue of Securities - BDA
|
11 December 2020 at 9:55am
|
|
Bod secures commitments to raise $8m via private placement
|
11 December 2020 at 9:55am
|
|
Trading Halt
|
10 December 2020 at 10:05am
|
|
Bod to benefit from US push to decriminalise cannabis
|
7 December 2020 at 9:50am
|
|
Bod to benefit from UN decision to reclassify cannabis
|
4 December 2020 at 9:45am
|
|
Bod broadens European footprint with binding purchase order
|
3 December 2020 at 9:45am
|
|
Results of Annual General Meeting
|
25 November 2020 at 3:15pm
|
|
CEO Presentation to Annual General Meeting
|
25 November 2020 at 9:45am
|
|
$1m binding purchase order received for Italian market entry
|
24 November 2020 at 9:50am
|
|
Strong growth in medicinal cannabis sales continues
|
17 November 2020 at 9:45am
|
|
Appendix 4G and Corporate Governance Statement
|
27 October 2020 at 1:45pm
|
|
Annual Report to shareholders
|
27 October 2020 at 1:45pm
|
|
Notice of Annual General Meeting and Proxy Form
|
23 October 2020 at 2:05pm
|
|
Bod launches CBD products in the Netherlands
|
20 October 2020 at 9:56am
|
|
Change of Director's Interest Notice
|
19 October 2020 at 8:00pm
|
Bod Australia